Studies comparing different diagnostic criteria for TA-TMA in the same cohort
| Study definition . | Adult TA-TMA incidence . | Pediatric TA-TMA incidence . | ||
|---|---|---|---|---|
| Empiric clinical diagnosis | Li 2009, Retrospective | 70/2145 (3%) | Schoettler 2020, Retrospective | 8/307 (3%) |
| C-TMA (modified Cho) | 192/2145 (9%) | 62/307 (20%) | ||
| New consensus (modified Jodele 4/7) | Not reported | 110/307 (36%) | ||
| Empiric clinical diagnosis | Vasu 2024, Prospective | 10/101 (10%) | Li 2023, Prospective | 4/32 (13%) |
| C-TMA (modified Cho) | Not reported | 5/32 (16%) | ||
| New consensus (modified Jodele 4/7) | 47/101 (47%) | 12/32 (38%) | ||
| Study definition . | Adult TA-TMA incidence . | Pediatric TA-TMA incidence . | ||
|---|---|---|---|---|
| Empiric clinical diagnosis | Li 2009, Retrospective | 70/2145 (3%) | Schoettler 2020, Retrospective | 8/307 (3%) |
| C-TMA (modified Cho) | 192/2145 (9%) | 62/307 (20%) | ||
| New consensus (modified Jodele 4/7) | Not reported | 110/307 (36%) | ||
| Empiric clinical diagnosis | Vasu 2024, Prospective | 10/101 (10%) | Li 2023, Prospective | 4/32 (13%) |
| C-TMA (modified Cho) | Not reported | 5/32 (16%) | ||
| New consensus (modified Jodele 4/7) | 47/101 (47%) | 12/32 (38%) | ||
Number of patients diagnosed with TA-TMA among total number of patients undergoing hematopoietic cell transplantation. The median follow-up duration varies by study from 100 days to 180 days.